�ٺ���Ƶ

News from �ٺ���Ƶ Health

‘I Had a Face Transplant – Now I’ve Found Love’. (Newsweek)
(1/14) “Eduardo D. Rodriguez, MD, DDS, the Helen L. Kimmel Professor of Reconstructive Plastic Surgery, chair, the Hansjörg Wyss Department of Plastic Surgery told Newsweek” that “the 2020 surgery” for Joe DiMeo “marked the first successful combination transplant case of its kind in the world.”

Chutes & Ladders. (Fierce Healthcare)
(1/12) reported in a roundup of executive moves in healthcare, “�ٺ���Ƶ Health, an integrated academic medical center, has promoted Joseph Lhota, Executive Vice President and Vice Dean, Chief of Staff, �ٺ���Ƶ Health to chief financial officer, replacing Daniel Widawsky on Feb. 1.”

Heart Failure Specialist to Lead �ٺ���Ƶ Health’s Cardio-Oncology Program. (Healio)
(1/13) reported, “Michelle Bloom, MD, professor, Department of Medicine, the Leon H. Charney Division of Cardiology, Division of Heart Failure has been named system director of the cardio-oncology program at �ٺ���Ƶ Health” which “provides specialized care to help protect cardiovascular health among people undergoing cancer treatment and cancer survivors.” Glenn I. Fishman, MD, the William Goldring Professor of Medicine, Department of Medicine, professor, Departments of Neuroscience and Physiology, and Biochemistry and Molecular Pharmacology, the Leon H. Charney Division of Cardiology, said in a press release, “Her experience as a clinician, educator and researcher will further enhance the �ٺ���Ƶ community. We look forward to a phase of significant clinical and academic advancement under her leadership in our program.”

Dr. Wise on the Impact of Genetic Testing on Patient Outcomes in Prostate Cancer. (OncLive)
(1/15) “David R. Wise, MD, PhD, assistant professor, Department of Medicine, Division of Hematology and Medical Oncology, and Department of Urology, Perlmutter Cancer Center, discusses his presentation from an OncLive State of the Science Summit on prostate cancer, during where he discussed the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).”

CtDNA Patterns May Predict Outcomes Achieved With MRNA-4157 Plus Pembrolizumab in High-Risk Melanoma. (OncLive)
(1/15) Jeffrey S. Weber, MD, PhD, the Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, Division of Hematology and Medical Oncology, Perlmutter Cancer Center said, “We’re going to see many patients on neoantigen vaccine trials in the next couple of years, and this [approach may] change the face of oncology.”

Are You Unwittingly Aiding the Rise of Superfungi? (Medscape)
Paywalled* (1/12)* Avrom S. Caplan, MD, assistant professor, the Ronald O. Perelman Department of Dermatology, at �ٺ���Ƶ Health in New York, “who reported the first cases of ringworm that only responded to oral medications in the United States, stressed that topical treatments work fine for many ringworm cases today.”
(Free log-in required.)

Dr. Rachel Goldman on the Complex World of Weight Loss Drugs. (Health Reporter)
(1/15) Rachel L. Goldman, PhD, clinical assistant professor, Department of Psychiatry, spoke to “Athletech News about weight loss drugs from a behavioral medicine perspective, and how the fitness and wellness industry can best support people taking GLP-1s.”

When Is the Best Time to Take Probiotics? Experts Explain. (TODAY)
(1/13) “Probiotics are live bacteria and yeast that are beneficial for the body. They supplement the microbiome, or create more diversity and improve the health of the bugs that live in the gut, Rabia A. De Latour, MD, assistant professor, Department of Medicine, Division of Gastroenterology and Hepatology at �ٺ���Ƶ Health, tells TODAY.com.”
Also reporting was (1/12).

Sodium Channels, Carbemazepine and Osteoarthritis Progression. (RheumNow)
(1/15) “Researchers from NYU Grossman School of Medicine and the Yale University School of Medicine noted that voltage-gated sodium channels (VGSCs) in chondrocytes and neurons may be involved in OA pathogenesis.”

Why Aren’t Folks Filling Heart Medication Prescriptions? (Seattle Medium)
(1/12) A “team of researchers at New York University’s (NYU) Grossman School of Medicine found a staggering gap in heart medication adherence along economic lines,” which “Saul B. Blecker, MD, associate professor, Departments of Population Health, and Medicine, Division of Internal Medicine at �ٺ���Ƶ, said their work should fuel investment in solutions for impacted people, ‘such as patient education programs and frequent follow-up with healthcare professionals.’”

Interstitial Lung Disease and Esophageal Disorders: When Specialties Work Together. (HMP Global Learning Network)
(1/16) “In this special podcast Rita Knotts, MD, assistant professor, Department of Medicine, Division of Esophageal Gastroenterology at NYU-Langone Health in New York City,” and “Dr Elizabeth Volkmann discuss the intersection of their specialties in the care of patients with scleroderma, interstitial lung disease, and esophageal conditions such as reflux.”

Taking Zepbound to Lose Weight? You Might Not Be Able to Stop. (Tacoma (WA) News Tribune)
(1/15) “Melanie R. Jay, MD, associate professor, Department of Medicine, Division of General Internal Medicine, and Department of Population Health, told the Times that 53 people exited the study” which “followed 670 overweight and obese people who took tirzepatide for nine months” due to “the side effects: nausea, diarrhea and constipation.”

These Twin Brothers Were Put to Bed One Night. Only One of Them Would Wake Up. (7 News (AUS))
(1/12) “Seizures during sleep are a potential cause of at least some cases of sudden unexplained death in childhood, or SUDC, researchers at �ٺ���Ƶ Health reported...after analysing home monitoring video that captured the deaths of seven sleeping toddlers.” Orrin Devinsky, MD, professor, Departments of Neurology, Neurosurgery, Psychiatry, director, Comprehensive Epilepsy Center at �ٺ���Ƶ and the study’s senior author, said, “We have video which is in some ways the best evidence we may ever get of what’s happened to these kids.” Laura Gould, MSc, MA, PT, research scientist, “co-founded the nonprofit SUDC Foundation and helped establish NYU’s registry of about 300 deaths – including the first seven videos offered by families – for research.”

US Researchers Estimate US$249B in Potential Healthcare Savings from Global Plastics Treaty Measures. (Packaging Insights)
(1/15) A study showing “plastics contribute substantially to disease and associated social costs in the US” which was “conducted at NYU Grossman School of Medicine, New York, stresses that actions through the UN Global Plastics Treaty and other policy initiatives could reduce these costs in proportion to the reduced chemical exposures.”

Florida Can Now Import Prescription Drugs from Canada. It’s Great News to My Patients. (USA Today)
(1/12) Marc K. Siegel, MD, clinical professor, Department of Medicine, Division of General Internal Medicine of �ٺ���Ƶ writes in an opinion piece, “The prescription drugs in Canada are just as effective and just as safe, as are generic and biosimilar drugs that can be had for much lower costs and yet often face approval challenges here.”

News from �ٺ���Ƶ Hospital—Long Island

NYU Names Director of Interventional Cardiology. (Becker's ASC Review)
(1/12) reported, “Dimitrios Bliagos, MD, clinical associate professor, Department of Medicine, Division of Cardiology, the Leon H. Charney Division of Cardiology, NYU Grossman Long Island School of Medicine, has been appointed director of interventional cardiology at �ٺ���Ƶ Hospital Long Island.” Bliagos “will also serve as clinical professor at NYU Grossman Long Island School of Medicine and as a clinical professor in the department of medicine and member of the Leon H. Charney Division of Cardiology at NYU Grossman School of Medicine in New York City.”

Addition Of Multifocal MRI-Directed SIB To SBRT Shows Acceptable Toxicity Profile in Prostate Cancer. (OncLive)
(1/12) Joshua C. Hurwitz, medical student at NYU Grossman Long Island School of Medicine, said, “We’ll hopefully be able to demonstrate that it is beneficial [with continued research].”

News from �ٺ���Ƶ Hospital—Brooklyn

Dr D’Abreo on the Evolution of ADC Use in the HER2+ Breast Cancer Treatment Landscape. (OncLive)
(1/15) “Nina D’Abreo, MD, assistant professor, Department of Medicine, chief, Division of Hematology and Medical Oncology, Perlmutter Cancer Center–Sunset Park, discusses the evolution of antibody-drug conjugates (ADCs) in the treatment of patients with HER2-low or HER2-positive breast cancer.”